Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies, FMC-220 demonstrated unprecedented potency and durable anti-tumor activity in vitro and in vivo at low doses. IND anticipated in 2H 2025Frontier’s pipeline of precision medicines continues to progress rapidly, with interim clinical data for FMC-376, an ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial, expected 2H 2025 BOSTON an ...